Trial Profile

Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Bendamustine and Rituximab (BR) in Patients With Previously Untreated Chronic Lymphocytic Leukaemia.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Fludarabine
Indications Chronic lymphocytic leukaemia
Focus Registrational; Therapeutic Use

08 Dec 2020 Results of pooled analysis (CLL7, CLL8, CLL10, CLL11 and CLL2M)presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
14 Feb 2018 Status changed from active, no longer recruiting to completed.
29 Aug 2016 Results (N=554) of this and other trial (CLL8) published in the Journal of Clinical Oncology (2016).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com